Kyverna Therapeutics (KYTX) Change in Accured Expenses (2023 - 2026)

Kyverna Therapeutics has reported Change in Accured Expenses for 4 years, with the latest figure at -$6.9 million in Q1 2026.

• For the quarter ending Q1 2026, Change in Accured Expenses fell 281.15% year-over-year to -$6.9 million; the trailing twelve-month figure through Mar 2026 stood at $35000.0 (down 97.96% YoY), and the FY2025 full-year result was $5.1 million, up 146.6% from the prior year.
• Change in Accured Expenses for Q1 2026 stood at -$6.9 million, down from $3.0 million in the prior quarter.
• The five-year high for Change in Accured Expenses was $3.0 million in Q4 2025, with the low at -$6.9 million in Q1 2026.
• Historically, Change in Accured Expenses has averaged $131000.0 across 4 years, with a median of $719000.0 in 2023.
• Annual changes were most pronounced in 2025 — Change in Accured Expenses surged 583.97% — and 2026, when it tumbled 281.15%.
• Kyverna Therapeutics' Change in Accured Expenses stood at $957000.0 in 2023, then plunged by 53.71% to $443000.0 in 2024, then surged by 583.97% to $3.0 million in 2025, then tumbled by 326.93% to -$6.9 million in 2026.
• The last three Change in Accured Expenses figures came in at -$6.9 million (Q1 2026), $3.0 million (Q4 2025), and $2.0 million (Q3 2025), per Business Quant data.